Carter Gould
Stock Analyst at Cantor Fitzgerald
(1.02)
# 2058
Out of 5,337 analysts
223
Total ratings
41.18%
Success rate
0.73%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
VRTX Vertex Pharmaceutica... | Reiterates: Overweight | 535 535 | 420.86 | 27.12% | 3 | May 6, 2025 | |
BMY Bristol-Myers Squibb | Reiterates: Neutral | 55 55 | 44.02 | 24.94% | 16 | Apr 23, 2025 | |
REGN Regeneron Pharmaceut... | Assumes: Overweight | 695 | 571.42 | 21.63% | 19 | Apr 22, 2025 | |
PFE Pfizer | Initiates Coverage On: Neutral | 24 | 21.99 | 9.14% | 15 | Apr 22, 2025 | |
PCVX Vaxcyte | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 85 | 73.52 | 15.61% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 975 | 714.62 | 36.44% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 125 | 98.31 | 27.15% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 210 | 177.25 | 18.48% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 160 165 | 118.83 | 38.85% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 20 | 21.12 | -5.3% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 190 180 | 120.42 | 49.48% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 300 315 | 262.09 | 20.19% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 100 | 71.15 | 40.55% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 3 | 0.17 | 1664.71% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 3 | 0.91 | 229.67% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 1.19 | 656.3% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 95 | 29.99 | 216.77% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 25 20 | 21.38 | -6.45% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 73 | 59.11 | 23.5% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 0.33 | 203.03% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 110 172 | n/a | n/a | 7 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 12 | 1.08 | 1011.11% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 2 | 1.02 | 47.06% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 15 | n/a | n/a | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 3 | 0.48 | 368.75% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 392 380 | 257.2 | 47.74% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 150 180 | n/a | n/a | 4 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 75 82 | 61.16 | 34.07% | 3 | Jan 16, 2019 |